In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including:

Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important
ADCs for HER2-negative/ultralow/low MBC
Patient communication: best practices in discussing treatment goals and potential AEs

Presenters:

Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine
University of California
Los Angeles, California

Ruta Rao, MD
Medical Director, Rush University Cancer Center
Professor of Medicine
Rush University Medical Center
Chicago, Illinois

Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Link to full program:
https://bit.ly/47JLtBt

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC